There are currently 196 active clinical trials seeking participants for Colorectal Cancer research studies. The states with the highest number of trials for Colorectal Cancer participants are California, Illinois, Ohio and New York.
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
NCT03597581
Recruiting
This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e., locally advanced and unresectable, or metastatic) previously treated colorectal adenocarcinoma. The single agent ompenaclid dose escalation stage and the ompenaclid in combination with FOLFIRI and bevacizumab dose escalation stage of the study has been completed; the expansion stage of ompenaclid in combination with FOLFIRI and bevacizumab is ongoin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Arizona Oncology Associates, PC - HAL, Prescott Valley, Arizona +16 locations
Conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
Register for Updates
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
NCT05722327
Recruiting
To find the recommended dose of MRTX849 that can be given in combination with cetuximab and irinotecan to patients with colorectal cancer that have a mutation (genetic change) called KRAS G12C.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Colon Cancer, Colorectal Cancer
Register for Updates
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
NCT05114798
Recruiting
Approximately 42% of American adults are obese, and this condition is strongly related to the development of colorectal cancer. Innovative lifestyle strategies to treat obesity and reduce colorectal cancer risk are critically needed. This research will demonstrate that time-restricted eating, a type of intermittent fasting, is an effective therapy to help obese individuals reduce and control their body weight and prevent the development of colorectal cancer.
Gender:
All
Ages:
Between 45 years and 70 years
Trial Updated:
05/07/2024
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Time Restricted Eating, Obesity, Weight Loss, Colorectal Cancer
Register for Updates
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
NCT05565417
Recruiting
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: Find the recommended dose of IMT-009 that can be safely given to participants Learn more about the side effects of IMT-009 Learn more about pharmacokinetics of IMT-009 Learn more about the effectiveness of IMT-009 Learn more about different pharmacokinetic b... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Site 9618, Tucson, Arizona +9 locations
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma
Register for Updates
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
NCT03998202
Recruiting
This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
Gender:
All
Ages:
60 years and above
Trial Updated:
04/30/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +164 locations
Conditions: Colorectal Cancer, Sarcopenia
Register for Updates
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
NCT05641896
Recruiting
Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma, cholangiocarcinoma, gastric, pancreatic and colorectal cancer. The [18F]FAPI-74 PET scan will be acquired in patients with proven GI cancers after initial staging using institutional standard methods. The PET scan results will be compared to FAP immunohistochemistry (as the p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: University of California Los Angeles (UCLA) Health, Los Angeles, California +4 locations
Conditions: Gastrointestinal Cancers, Cholangiocarcinoma, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Hepatocellular Carcinoma
Register for Updates
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519
Recruiting
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Yale Cancer Center, New Haven, Connecticut +4 locations
Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Epithelial Ovarian Cancer, BRCA2 Mutation, ER+ Breast Cancer, Castrate Resistant Prostate Cancer, BRCA1 Mutation, BRCA Mutation, Endometrial Cancer, Colorectal Cancer, Gastric Cancer
Register for Updates
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
NCT05200442
Recruiting
Doctors leading this study hope to learn about the safety of combining the study drug VS-6766 with another drug called cetuximab in colorectal cancer. This study is for individuals who have advanced colorectal cancer and their cancer has progressed while getting previous treatment or individuals who cannot take/tolerate previous treatments. If you choose to participate, your time in this research will last up to 24 months.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
Register for Updates
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
NCT04844073
Recruiting
The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer. Another aim is to characterize and evaluate the activity of TAK-186 (MVC-101). Participants may receive treatment throughout the study for a maximum of 13 months and will be followed up at 30 days and 90 days and then every 12 weeks for up to 48 weeks after the last treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: University of California San Francisco, San Francisco, California +17 locations
Conditions: Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
Register for Updates
Preserving Fertility After Colorectal Cancer Study
NCT05239338
Recruiting
The PREFACE Study is a prospective, longitudinal cohort study of reproductive health and clinical outcomes among individuals diagnosed with colorectal cancer between age 18 to 49 years.
Gender:
All
Ages:
Between 18 years and 49 years
Trial Updated:
04/29/2024
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Colorectal Cancer
Register for Updates
ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension
NCT05056896
Recruiting
This research study is studying a drug intervention as a possible chemoprevention strategy for colorectal cancer. The name of the study intervention involved in this study is: Low Dose Aspirin
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Colorectal Cancer
Register for Updates
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05585034
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: UCLA Hematology/Oncology, Los Angeles, California +11 locations
Conditions: Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
Register for Updates